Breaking News

Rithem Life Sciences Joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation

The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.

1st Patients Enrolled in STEM Trial for `Treatment of Chronic Subdural Hematoma

This marks the first patients enrolled in a prospective, randomized, international trial of a liquid embolic agent for the treatment of chronic subdural hematoma (cSDH), a common disease affecting primarily older adults.

Genius AI Detection Receives FDA Clearance – New Deep Learning-based Software Designed to Help Radiologists Detect Subtle Potential Cancers in Breast Tomosynthesis Images

This new technology, represents a pivotal milestone in the early detection of breast cancer, as studies showed Genius AI Detection software aids in the identification and early detection of breast cancer when used with the Genius® 3D Mammography™ exam.

Passio Pump Drainage System Granted 510(k) for Additional Indication for Home Use

The Passio Pump Drainage System consists of the Passio Catheter, a Handheld Control Unit (pump) and a Disposable Collection Kit, which includes a redressing kit, for drainage of recurrent and symptomatic pleural effusion.

Boston Scientific Signs Definitive Agreement to Divest BTG Specialty Pharmaceuticals Business

Boston Scientific notes SERB, backed by private equity firm Charterhouse Capital Partners since 2017, owns a diversified portfolio of prescription medicines focused on rare and life-threatening diseases.

QT Ultrasound Partners with Shanghai-Based TCL Healthcare Equipment

September 10, 2020

QT Ultrasound, developer of the QTscan®, will bring its radiation- and compression-free 3D breast imaging technology to China, and other Asian markets, through a partnership with TCL Healthcare Equipment. The Shanghai-based company focuses on medical imaging equipment with proven expertise in bringing innovative products to Asia.

QT Ultrasound focused on China for international expansion because China is the second-largest medical device market in the world, following the United States. The market will continue to grow because the Chinese government is focused on improving healthcare access and outcomes by embracing technological innovation. The QTscan is particularly advantageous for Asian women because of its ability to accurately image dense breasts; an estimated 70% of Asian women have dense breasts, for which mammography has proven to be less sensitive in identifying masses. Both companies believe China is a country where the QTscan can have a very positive impact on women’s healthcare.

“QT Ultrasound is excited to partner with TCL Healthcare to bring our safe, innovative breast imaging technology to China. This team has the knowledge, experience, and relationships to take the QT Ultrasound Breast Scanner from approval through commercialization. We could not have found better partners,” says QT Ultrasound’s CEO and Founder, Dr. John Klock.

Mr. George Chan, Chairman of TCL Healthcare, understands that for health care to help save more lives, it needs to be affordable, which became the company’s mission. Mr. Chan says, “The QT Ultrasound Breast Scanner is exactly the right technology at the right time and will further our goal of screening for common cancers, especially screening for women – quickly, safely, and affordably.”

QT Ultrasound and TCL Healthcare share ambitious goals for providing women across Asia access to the QTscan. They expect to quickly commercialize the QTscan in China’s healthcare institutions and become a leader in the rapidly growing, breast imaging arena.

 

Latest Posts

Rithem Life Sciences Joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation

The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.

1st Patients Enrolled in STEM Trial for `Treatment of Chronic Subdural Hematoma

This marks the first patients enrolled in a prospective, randomized, international trial of a liquid embolic agent for the treatment of chronic subdural hematoma (cSDH), a common disease affecting primarily older adults.

New England Biolabs Announces Further Expansion of Their RNA Depletion Product Portfolio with the Launch of the NEBNext Custom RNA Depletion Design Tool and NEBNext RNA Depletion Core Reagent...

Together, these enable a fully customizable workflow for improved removal of specific RNAs, including abundant RNAs such as ribosomal RNA

Don't Miss

New England Biolabs Announces Further Expansion of Their RNA Depletion Product Portfolio with the Launch of the NEBNext Custom RNA Depletion Design Tool and NEBNext RNA Depletion Core Reagent...

Together, these enable a fully customizable workflow for improved removal of specific RNAs, including abundant RNAs such as ribosomal RNA

INTERCEPT Blood System for Cryoprecipitation Receives FDA Approval States Cerus Corporation

The system is used to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. 

Genetron Health Provides Update on HCCscreen™ for Liver Cancer Early Screening in China

Establishes joint venture with Wuxi municipal government; Expects the commercialization and revenues of HCCscreen to accelerate in China.

Research Paper Showing ProtoKinetix AAGP® Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision

ProtoKinetix notes the research paper has been submitted to a prestigious journal specializing in tissue regeneration for peer review and editing.

OrganaBio to Expand Its cGMP Cell and Gene Therapy Manufacturing Facility: 19,000 Sq. Ft. Slated to Commence Operations In Q3 2021

OrganBio, a Miami-based cGMP facility, will include process development space, ISO 7 cleanrooms, state-of-the-art scientific equipment, analytics and QC laboratories, and a suite of support services to enable OrganaBio and its partners to rapidly and economically self-manufacture clinical materials.